Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: L04AC08

Canakinumab Novartis(canakinumab)

Acute Coronary Syndrome;Myocardial Infarction;Stroke

Marketing Authorisation Holder: Novartis Europharm Limited

INN: canakinumab

Indication

Prevention of major cardiovascular events

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Canakinumab Novartis — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.